CEBPA and acute myeloid leukemia: Furthermore, an animal model demonstrated that ASXL1‐G643W mutations (the most common mutation according to the authors) contributed to the development of CEBPA‐driven AML, which is involved in the resistance to chemotherapy.23, 49